Med Clin North Am. 2015 Jan;99(1):107-129
Authors: Neumiller JJ
Incretin hormones, namely glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide, have been recognized for some time as playing a key role in glucose homeostasis, with the effects of incretin hormones believed to be responsible for up to 60% of postprandial insulin release. Two predominant therapeutic strategies have been developed to augment the incretin response: (1) GLP-1 receptor agonists resistant to degradation by the enzyme dipeptidyl peptidase 4 (DPP-4); and (2) DPP-4 inhibitors. With an expanding arsenal of incretin-based therapies available, understanding the differentiating efficacy and safety profiles for available agents is important in optimizing drug selection and patient outcomes.
PMID: 25456646 [PubMed - as supplied by publisher]